Trade Karuna Therapeutics, Inc. - KRTX CFD

Karuna Therapeutics, Inc. Company profile

About Karuna Therapeutics Inc

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Karuna Therapeutics Inc revenues increased from $0K to $37M. Net loss increased from $68.6M to $143.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $32.3M to $98.7M (expense), General and administrative - Other increase from $6.5M to $25.2M (expense).